This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:diseases:ibs [03.13.2019] – [Headline] sallieq | home:diseases:ibs [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 6: | Line 6: | ||
- | Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits. | + | Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits. |
- | However, the notion that IBS is a psychological disorder has come under serious challenge.(({{pubmed> | + | However, the notion that IBS is a psychological disorder has come under serious challenge.(({{pmid> |
The Marshall Protocol treats IBS by reactivating the innate immune response. In the course of treatment, patients' | The Marshall Protocol treats IBS by reactivating the innate immune response. In the course of treatment, patients' | ||
Line 17: | Line 17: | ||
* **constipation** – MP patients with constipation should have the symptom treated for immediate relief and then measures should be adopted to prevent constipation. | * **constipation** – MP patients with constipation should have the symptom treated for immediate relief and then measures should be adopted to prevent constipation. | ||
- | * **diarrhea** – Patients with diarrhea may wish to increase fluid intake and/or take anti-diarrheal medication. | + | * **diarrhea** – Patients with diarrhea may wish to increase fluid intake and/or take anti-diarrheal medication. |
* **[[home: | * **[[home: | ||
- | [{{ : | + | [{{ : |
===== Evidence of infectious cause ===== | ===== Evidence of infectious cause ===== | ||
Line 26: | Line 26: | ||
< | < | ||
- | // | + | // |
==== Onset following gastrointestinal infection ==== | ==== Onset following gastrointestinal infection ==== | ||
- | Epidemiologic studies have shown that gastrointestinal infection is the strongest environmental risk factor for the development of IBS.(({{pubmed> | + | Epidemiologic studies have shown that gastrointestinal infection is the strongest environmental risk factor for the development of IBS.(({{pmid> |
Line 36: | Line 36: | ||
==== Abnormal composition ==== | ==== Abnormal composition ==== | ||
- | Small intestinal bacterial overgrowth (SIBO) has been documented in a proportion of patients with IBS (10%–84%). For example, in 2012, Greek researchers enrolled patients needing upper gastrointestinal (GI) tract endoscopy. Among 320 subjects SIBO was diagnosed in 62 (19.4%) with 42 of those having IBS (67.7%). Of all IBS sufferers, SIBO was found in 37.5%. // | + | Small intestinal bacterial overgrowth (SIBO) has been documented in a proportion of patients with IBS (10%–84%). For example, in 2012, Greek researchers enrolled patients needing upper gastrointestinal (GI) tract endoscopy. Among 320 subjects SIBO was diagnosed in 62 (19.4%) with 42 of those having IBS (67.7%). Of all IBS sufferers, SIBO was found in 37.5%. // |
==== Higher temporal instability ==== | ==== Higher temporal instability ==== | ||
- | Accumulating evidence shows that patients with IBS have a higher temporal instability of the bacterial populations and that the microbiota composition is different compared with healthy controls.(({{pubmed> | + | Accumulating evidence shows that patients with IBS have a higher temporal instability of the bacterial populations and that the microbiota composition is different compared with healthy controls.(({{pmid> |
==== Headline ==== | ==== Headline ==== | ||
- | Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. | + | Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. |
- | ==== Further | + | ==== Further |
- | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | + | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. |
+ | |||
+ | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. | ||
+ | |||
+ | Mast cell activation syndromes | ||
+ | |||
+ | Gastrointestinal (GI) symptoms are commonly reported in patients with mast cell disease. | ||
+ | |||
+ | Mast cells are located in close proximity to the vasculature, | ||
+ | |||
+ | Mast cell activation plays an important role in stress-mediated disease pathogenesis. | ||
- | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. | ||
Line 72: | Line 81: | ||
Lyme disease, irritable bowel syndrome/ | Lyme disease, irritable bowel syndrome/ | ||
- | Read the [[http:// | + | Read the [[https:// |
< | < | ||
Line 87: | Line 96: | ||
diabetes, sarcoidosis, | diabetes, sarcoidosis, | ||
- | Read the [[http:// | + | Read the [[https:// |
< | < | ||
Line 111: | Line 120: | ||
{{tag> | {{tag> | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | ===== References ===== | + | ===== References =====</ |